ArticleDiabetes2015
Engineered commensal bacteria reprogram intestinal cells into glucose-responsive insulin-secreting cells for the treatment of diabetes.
Article in Diabetes, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
102 citing papers in PubMed, 251 citations in OpenAlex.
- Engineering commensal microbes for host health.Cell host & microbe · 2026Review
- The Gut-Liver Axis in MASLD: From Host-Microbiome Crosstalk to Precision Therapeutics.Microorganisms · 2026Review
- Engineered bacteria: a novel era for metabolic, cardiovascular and cerebrovascular diseases therapy.Frontiers in cardiovascular medicine · 2026Review
- Updated Insights into Probiotic Interventions for Metabolic Syndrome: Mechanisms and Evidence.Probiotics and antimicrobial proteins · 2026Review
- Being a better version of yourself: genetically engineered probiotic bacteria as host defense enhancers in the control of intestinal pathogens.Gut microbes · 2025Review
- The microbiota-gut-brain-axis theory: role of gut microbiota modulators (GMMs) in gastrointestinal, neurological, and mental health disorders.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- A genetic safeguard for eliminating target genes in synthetic probiotics in a gut environment.iScience · 2025Article
- Oral delivery of GLP-1 peptide using recombinantMicrobiology spectrum · 2025Article
- Be a GEM: Biocontained, environmentally applied, genetically engineered microbes.Advanced drug delivery reviews · 2025Review
- Review
- Metabolic engineering of Lactobacilli spp. for disease treatment.Microbial cell factories · 2025Review
- Oral delivery of therapeutic proteins by engineered bacterial type zero secretion system.Nature communications · 2025Article
- Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease.Clinical and molecular hepatology · 2025Review
- Olivetol's Effects on Metabolic State and Gut Microbiota Functionality in Mouse Models of Alimentary Obesity, Diabetes Mellitus Type 1 and 2, and Hypercholesterolemia.Biomedicines · 2025Article
- Genetic improvement of a synthetic microbiota: a step further?Frontiers in microbiology · 2025Article
- β-cell heterogeneity and molecular plasticity in type 2 diabetes: multi-omics perspectives and the role of gut microbiota.Frontiers in cell and developmental biology · 2025Review
- Engineered Bacteria for Disease Diagnosis and Treatment Using Synthetic Biology.Microbial biotechnology · 2025Review
- Bacteria Engineered to Produce Serotonin Modulate Host Intestinal Physiology.ACS synthetic biology · 2024Article
- The Role and Mechanism of Probiotics Supplementation in Blood Glucose Regulation: A Review.Foods (Basel, Switzerland) · 2024Review
- Review
42 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The inactive full-length form of GLP-1(1-37) stimulates conversion of both rat and human intestinal epithelial cells into insulin-secreting cells. We investigated whether oral administration of human commensal bacteria engineered to secrete GLP-1(1-37) could ameliorate hyperglycemia in a rat model of diabetes by reprogramming intestinal cells into glucose-responsive insulin-secreting cells. Diabetic rats were fed daily with human lactobacilli engineered to secrete GLP-1(1-37). Diabetic rats fed GLP-1-secreting bacteria showed significant increases in insulin levels and, additionally, were significantly more glucose tolerant than those fed the parent bacterial strain. These rats developed insulin-producing cells within the upper intestine in numbers sufficient to replace ∼25-33% of the insulin capacity of nondiabetic healthy rats. Intestinal tissues in rats with reprogrammed cells expressed MafA, PDX-1, and FoxA2. HNF-6 expression was observed only in crypt epithelia expressing insulin and not in epithelia located higher on the villous axis. Staining for other cell markers in rats treated with GLP-1(1-37)-secreting bacteria suggested that normal function was not inhibited by the close physical proximity of reprogrammed cells. These results provide evidence of the potential for a safe and effective nonabsorbed oral treatment for diabetes and support the concept of engineered commensal bacterial signaling to mediate enteric cell function in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.